非酒精性脂肪性肝病与心脏:JACC最新综述
非酒精性脂肪性肝病(NAFLD)与心血管疾病(CVD)均为代谢综合征的终末器官损害表现,通过全身炎症、内皮功能障碍、肝脏胰岛素抵抗、氧化应激及脂代谢改变等机制相互关联。NAFLD可加重动脉粥样硬化、心肌病和心律失常,导致心血管发病率和死亡率升高。本综述旨在探讨两者关联及重叠的管理策略。
要点
- NAFLD与CVD通过代谢综合征相关机制相互关联,增加心血管风险。
- NAFLD患者动脉粥样硬化、心肌病和心律失常发生率增加。
- 针对共同机制的管理策略可能改善两者预后。
核心结论
- NAFLD通过多种病理生理机制增加CVD风险,两者存在重叠的管理方法。
研究设计与样本
- 本文为JACC的综合性综述,旨在探讨CVD与NAFLD的关联及重叠管理策略。
主要发现
- NAFLD通过全身炎症、内皮功能障碍、肝脏胰岛素抵抗、氧化应激和脂代谢改变等机制增加CVD风险。
- NAFLD患者动脉粥样硬化、心肌病和心律失常增加,导致心血管发病和死亡。
临床怎么用
- 临床应认识到NAFLD患者的心血管风险增加,并考虑针对共同机制的管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are both manifestations of end-organ damage of the metabolic syndrome. Through multiple pathophysiological mechanisms, CVD and NAFLD are associated with each other. Systemic inflammation, endothelial dysfunction, hepatic insulin resistance, oxidative stress, and altered lipid metabolism are some of the mechanisms by which NAFLD increases the risk of CVD. Patients with NAFLD develop increased atherosclerosis, cardiomyopathy, and arrhythmia, which clinically result in cardiovascular morbidity and mortality. Defining the mechanisms linking these 2 diseases offers the opportunity to further develop targeted therapies. The aim of this comprehensive review is to examine the association between CVD and NAFLD and discuss the overlapping management approaches.
引用
- Stahl EP, Dhindsa DS, Lee SK, et al. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019. PMID: 30819364. doi:10.1016/j.jacc.2018.11.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。